Horizon Discovery Group plc (“Horizon” or “the Company”), the revenue generating life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines, comments on the recent share price movement below.
“Horizon continues to trade strongly since the IPO, at least in line with expectations and we are actively pursuing the Company’s stated strategy to make strategic acquisitions and expanding our IP portfolio, geographic footprint, sales and distribution channels.” stated Dr Darrin M Disley, Chief Executive Officer of Horizon Discovery Group plc.
For further information please contact:
Consilium Strategic Communications
Amber Bielecka / Mary-Jane Elliott / Jessica Hodgson / Matthew Neal
+44 207 920 2352
Panmure Gordon and Co.
As Nominated Adviser and Broker
Freddy Crossley / Duncan Monteith / Fred Walsh
Tom Salvesen/ Adam Pollock
Tel: +44 20 7886 2500
About Horizon Discovery Group plc
Horizon is a revenue-generating life science company supplying research tools to organizations engaged in genomics research and the development of personalized medicines. Horizon has a diverse and international customer base approaching 800 organizations, including major pharmaceutical, biotechnology and diagnostic companies as well as leading academic research centres. The Company supplies its products and services into multiple markets, estimated to total in excess of £29 billion by 2015.
Horizon’s core capabilities are built around its proprietary translational genomics platform, GENESIS™, a high-precision and flexible suite of gene editing tools. Horizon has applied GENESIS™ to create over 500 X-MAN™ cell lines, accurately modeling the disease-causing mutations found in genetically based diseases. These ‘patients-in-a-test-tube’ are being used by customers to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, which may lead to the successful prediction of which patient sub-groups will respond to currently-available and future drug treatments.